IGM Biosciences Inc (NASDAQ:IGMS) — Market Cap & Net Worth
Market Cap & Net Worth: IGM Biosciences Inc (IGMS)
IGM Biosciences Inc (NASDAQ:IGMS) has a market capitalization of $46.47 Million ($46.47 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22253 globally and #4940 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IGM Biosciences Inc's stock price $1.27 by its total outstanding shares 36593200 (36.59 Million). Also see IGMS total assets for a full breakdown of the balance sheet.
IGM Biosciences Inc Market Cap History: 2019 to 2025
IGM Biosciences Inc's market capitalization history from 2019 to 2025. Data shows change from $1.40 Billion to $46.47 Million (-39.33% CAGR). Also see IGMS cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
IGM Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #643 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2115 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.00% | #249 of 263 |
Weight: IGM Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
IGM Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IGM Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of IGM Biosciences Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
83.46x
IGM Biosciences Inc's market cap is 83.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.07 Billion | $366.00K | -$160.68 Million | 2932.46x | N/A |
| 2022 | $622.45 Million | $1.07 Million | -$214.25 Million | 582.27x | N/A |
| 2023 | $304.09 Million | $2.13 Million | -$246.42 Million | 142.77x | N/A |
| 2024 | $223.58 Million | $2.68 Million | -$195.79 Million | 83.46x | N/A |
Competitor Companies of IGMS by Market Capitalization
Companies near IGM Biosciences Inc in the global market cap rankings as of September 18, 2026. Review IGMS tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to IGM Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
IGM Biosciences Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, IGM Biosciences Inc's market cap moved from $1.40 Billion to $ 46.47 Million, with a yearly change of -39.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $46.47 Million | -79.21% |
| 2024 | $223.58 Million | -26.47% |
| 2023 | $304.09 Million | -51.15% |
| 2022 | $622.45 Million | -42.00% |
| 2021 | $1.07 Billion | -66.78% |
| 2020 | $3.23 Billion | +131.37% |
| 2019 | $1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 12th, 2026 the market cap of IGM Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.47 Million USD |
| MoneyControl | $46.47 Million USD |
| MarketWatch | $46.47 Million USD |
| marketcap.company | $46.47 Million USD |
| Reuters | $46.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more